Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-07-22 Environmental & Social …
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Updates
Environmental & Social Information Classification · 95% confidence The document is titled 'Business Responsibility and Sustainability Report' for the financial year 2024-25 and is addressed to stock exchanges as per SEBI regulations. It contains detailed disclosures on sustainability strategy, environmental protection, social responsibility, governance, employee data, and CSR details. The content focuses on Environmental, Social, and Governance (ESG) factors and sustainability commitments rather than financial results or corporate governance changes. The length is substantial (15,000 characters), indicating it is the full report, not just an announcement. This matches the description of an Environmental & Social Information report (ESG report). Therefore, the appropriate classification is 'SR' (Environmental & Social Information).
2025-07-22 English
Updates
AGM Information Classification · 100% confidence The document is a Notice of the 46th Annual General Meeting (AGM) of AstraZeneca Pharma India Limited scheduled for August 14, 2025. It includes details about the meeting agenda such as adoption of financial statements for the year ended March 31, 2025, dividend declaration, appointment of directors, and other resolutions. The document references the Annual Report for the financial year 2024-25 being available on the company's website but does not contain the full report itself. The content is typical of an AGM Notice, which is a formal communication sent to shareholders to inform them about the meeting and the business to be transacted. It is not the Annual Report (10-K), nor a report publication announcement (RPA) since it includes detailed agenda items and resolutions. Therefore, the appropriate classification is AGM Information (AGM-R).
2025-07-22 English
Please find the enclosed Business Responsibility and Sustainability Report for the financial year 2024-25.
Environmental & Social Information Classification · 95% confidence The document is titled 'Business Responsibility and Sustainability Report' for the financial year 2024-25 and is submitted pursuant to SEBI regulations. It contains detailed disclosures on sustainability strategy, environmental protection, social responsibility, governance, employee data, grievance redressal, and CSR details. The content focuses on Environmental, Social, and Governance (ESG) factors and sustainability commitments rather than financial performance or management changes. The document length is substantial (15,000 characters) and contains the full report, not just an announcement or a certification. Therefore, it fits the category of Environmental & Social Information (SR).
2025-07-22 English
Please find the enclosed Notice of the AGM scheduled to be held on Thursday, August 14, 2025 at 3:00 p.m. IST.
AGM Information Classification · 95% confidence The document is a Notice of the 46th Annual General Meeting (AGM) of AstraZeneca Pharma India Limited scheduled for August 14, 2025. It includes details about the meeting agenda such as adoption of financial statements for the year ended March 31, 2025, dividend declaration, appointment of directors, and other resolutions. The document references the Annual Report for the financial year 2024-25 being available on the company's website but does not contain the full report itself. The content is typical of an AGM Notice, which is a formal communication sent to shareholders to inform them about the meeting and the business to be transacted. It is not the Annual Report itself, nor is it a voting results announcement or proxy solicitation. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (15,000 characters) supports it being a detailed AGM Notice rather than a brief announcement or a full report.
2025-07-22 English
Please find the enclosed copy of the Annual Report for the financial year 2024-25 for your reference.
Annual Report Classification · 100% confidence The document is a detailed communication addressed to stock exchanges regarding the Annual Report for the financial year ended March 31, 2025. It references the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and explicitly states that the Annual Report is enclosed. The content includes a Managing Director's statement, corporate overview, statutory reports, financial statements, auditor's report, balance sheet, profit and loss statement, and other comprehensive sections typical of a full Annual Report. The document length is substantial (15,000 characters), indicating it is the report itself rather than a brief announcement or notice. Therefore, this document fits the definition of an Annual Report (10-K).
2025-07-22 English
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the listing managers of BSE Limited and National Stock Exchange of India Limited. It discusses communication to shareholders regarding Tax Deducted at Source (TDS) on dividends for the financial year 2024-25. The letter mentions that the communication has been sent to shareholders and a specimen of the communication is appended for reference. There is no detailed financial data, financial statements, or comprehensive report content. The document is essentially an announcement or notification about shareholder communication related to dividend tax matters. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Dividend Notice since it focuses on communication about TDS on dividends rather than the dividend amount or payment details. Given the nature of the document as a communication to stock exchanges about shareholder communication, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2025-07-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.